2020 American Transplant Congress
Crispr-Based Diagnostics for Rejection and Opportunistic Infection Detection in Kidney Transplantation
*Purpose: There is an unmet need in transplantation to identify allograft injury non-invasively. More than 50% of patients with kidney transplants lose their grafts within…2020 American Transplant Congress
Efficacy and Safety According to Dose of Valganciclovir for Cytomegalovirus Prophylaxis in Transplantation Network Meta Analysis
Inha University, Incheon, Korea, Republic of
*Purpose: Valgancivlovir is importantly used to prevent post-transplant CMV infection among kidney transplantation patients. However, the dose of such drug being used still remains controversial…2020 American Transplant Congress
Multicenter Evaluation of Cytomegalovirus Infection Following Intestinal and Multivisceral Transplantation
1Duke University Hospital, Chapel Hill, NC, 2Henry Ford Hospital, Detroit, MI
*Purpose: Evaluate factors related to incidence and outcomes of cytomegalovirus (CMV) infection after isolated intestinal transplantation (IT) and multivisceral transplantation (MVT).*Methods: Retrospective evaluation of 32…2020 American Transplant Congress
Conversion to Sirolimus to Prevent Recurrent Cytomegalovirus Infection/Disease: A Prospective and Randomized Trial
Hospital do Rim - UNIFESP, São Paulo, Brazil
*Purpose: Recurrent cytomegalovirus (CMV) infection occurs in 30-35% of kidney transplant recipients after completion of treatment and/or preemptive therapy. There is no consensus on the…2020 American Transplant Congress
Influence of HLA Compatibility on Cytomegalovirus Infection Post-Kidney Transplantation
*Purpose: Cytomegalovirus (CMV) infection after kidney transplantation is associated with a high morbidity and higher risk of graft loss. A latent Human CMV infection can…2020 American Transplant Congress
Identification of Cell Types That Harbor Cytomegalovirus DNA in Acutely and Latently Infected Mice Spleen
*Purpose: Cytomegalovirus (CMV) is a ubiquitous β‐herpesvirus that infects majority of humans. Primary CMV infection may be asymptomatic or manifests as a self‐limited febrile illness…2020 American Transplant Congress
Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens
Pharmacy, Ann and Robert H. Lurie Children's Hospital, Chicago, IL
*Purpose: Valganciclovir (VGCV) is FDA-approved for CMV prophylaxis in children aged one month to sixteen years old using the Pescovitz algorithm (7 x body surface…2020 American Transplant Congress
The Value of Pharmacist-Driven Valganciclovir Dosing in Kidney Transplant Recipients in Reducing CMV Infection: A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is a common viral infection after kidney transplant (KT) despite prophylaxis with valganciclovir (VGCV). VGCV is renally dosed and can be a…2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…2020 American Transplant Congress
Reduced Dose Valganciclovir is Effective for CMV Prevention without Excess Breakthrough or Resistance in Kidney Transplantation
*Purpose: Reduced dose valganciclovir (VGC) (450 mg daily) may be a useful alternative to full dose VGC for cytomegalovirus (CMV) prophylaxis due to drug cost…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 33
- Next Page »